CC
SONM icon

Cannell Capital’s DNA X Inc SONM Stock Holding History

Cannell Capital’s Portfolio SONM Stock Details SONM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,626
Closed -$42.9K – 59
2025
Q4 		$42.9K Buy
+13,626
New +$122K 0.02% 51
2020
Q3 		– Sell
-209
Closed -$301K – 49
2020
Q2 		$301K Sell
209
-216
-51% -$345K 0.11% 44
2020
Q1 		$535K Buy
425
+109
+34% +$522K 0.22% 43
2019
Q4 		$2.07M Buy
+316
New +$1.56M 0.67% 28
2019
Q3 		– Sell
-278
Closed -$6.36M – 49
2019
Q2 		$6.36M Buy
+278
New +$7.05M 1.8% 21

Other funds holding SONM

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CWM
C2C Wealth Management Scottsdale, Arizona $128M AUM 22.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $41.5B AUM 29.19% 1-Year Est. Return

Cannell Capital's SONM Position: Q1 2026 in Review

Cannell Capital sold out of DNA X Inc (SONM) in Q1 2026, closing a stake of 13,626 shares — an estimated $42.9K sold.

Cannell Capital first reported a position in SONM in Q2 2019 and held it in 5 quarters. The position peaked at $6.36M in Q2 2019. 9 funds tracked by Wall St. Rank hold SONM as of Q1 2026.

  • Cannell Capital reported no remaining DNA X Inc position as of Q1 2026 after selling out during the quarter.
  • Cannell Capital sold 13,626 DNA X Inc shares in Q1 2026, an estimated $42.9K.
  • Cannell Capital first reported a position in DNA X Inc in Q2 2019 and held it in 5 quarters.
  • Cannell Capital's DNA X Inc position peaked at $6.36M in Q2 2019.
  • 9 funds tracked by Wall St. Rank held DNA X Inc as of Q1 2026.

Based on Cannell Capital's 13F filing for Q1 2026, filed 15 May 2026.